Abstracts tagged "Vasculitis"

Abstract Number: 1348 • ACR Convergence 2023
Reproductive Outcomes for Women with Vasculitis
Catherine Sims¹, Christine Yeung², Heather Tam³, Joyce Kullman⁴, Amanda Eudy⁵, Renee Borchin⁶, Cristina Burroughs⁶, Megan Clowse⁷ and Peter Merkel², ¹Duke University School of Medicine, Durham, NC, ²University of Pennsylvania, Philadelphia, PA, ³Vasculitis Patient Powered Research Network, Stanford, CA, ⁴Vasculitis Foundation, Kansas City, MO, ⁵Duke University, Raleigh, NC, ⁶University of South Florida, Tampa, FL, ⁷Duke University, Chapel Hill, NC
Background/Purpose: There are limited data on the reproductive health of women with vasculitis. This study utilized a large, prospective, international vasculitis pregnancy registry to survey…
Abstract Number: 1568 • ACR Convergence 2023
Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu’s Arteritis
Sema Kaymaz-Tahra¹, Ozun Bayindir Tsechelidis², Burak Ince³, Ozlem Ozdemir Isik⁴, Muhammet Emin Kutu⁵, Ozlem Karakas⁶, Tuba Demirci Yildirim⁷, Zeliha Ademoglu⁸, Elif Durak Ediboglu⁹, Burcu Ceren Ekti Uludogan¹⁰, Can Ilgin¹¹, Sule Yasar Bilge¹², Timucin Kasifoğlu¹², Servet Akar⁹, Hakan Emmungil⁸, Fatos Onen¹³, Ahmet Omma⁶, Nilufer Alpay Kanitez¹⁴, Ayten Yazici⁴, Ayse Cefle¹⁵, Murat Inanç¹⁶, Kenan Aksu¹⁷, Gökhan Keser¹⁷, Haner Direskeneli¹⁸ and fatma Alibaz-Öner¹⁹, ¹Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey, ²Ottawa University, Ottawa, ON, Canada, ³Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ⁵Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁶Ankara City Hospital, Ankara, Turkey, ⁷Dokuz Eylul University, Izmir, Turkey, ⁸Trakya University Faculty of Medicine, Edirne, Turkey, ⁹Katip Celebi University Faculty of Medicine, Izmir, Turkey, ¹⁰Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ¹¹Marmara University Faculty of Medicine, Istanbul, Turkey, ¹²Division of Rheumatology, Medical School, Osmangazi University, Eskişehir, Turkey, ¹³Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁴Koc University Faculty of Medicine, Istanbul, Turkey, ¹⁵Division of Rheumatology, Medical School, Kocaeli University, Kocaeli, Turkey, ¹⁶Istanbul University, Istanbul, Turkey, ¹⁷Division of Rheumatology, Medical School, Ege University, Izmir, Turkey, ¹⁸Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁹Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Conventional disease-modifying anti-rheumatic drugs (cDMARDs) are recommended in addition to glucocorticoids (GC) for all active Takayasu's arteritis (TAK) patients as the first-line therapy. However,…
Abstract Number: 2370 • ACR Convergence 2023
C5 as a Genetic Marker for Discriminating Between IgA Vasculitis and IgA Nephropathy?
JOAO CARLOS BATISTA LIZ¹, Vanesa Calvo Río², María Sebastián Mora-Gil¹, Belén Sevilla-Pérez³, María Teresa Leonardo⁴, Ana Peñalba⁴, María Jesús Cabero⁴, Javier Narvaez⁵, luis martin penagos⁶, Emilio Rodrigo⁶, Lara Belmar-Vega⁶, Cristina Gomez-Fernandez⁷, Luis Caminal-Montero⁸, Paz Collado⁹, Antonio Fernandez-Nebro¹⁰, gisela Díaz-Cordovés¹¹, Maryia Nikitsina¹², Esther Vicente Rabaneda¹³, secundino Cigarrán¹⁴, jesús Calviño¹⁵, carmen cobelo¹⁵, Manuel León Luque¹⁶, Esteban Rubio¹⁶, Juan María Blanco-Madrigal¹⁷, Eva Galindez-Agirregoikoa¹⁸, Santos Castañeda¹⁹, Ricardo Blanco²⁰, Verónica Pulito-Cueto¹ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Valdecilla Hospital, Santander, Spain, ³Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁴Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, ⁷Division of Dermatology,Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁸Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ⁹Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, ¹⁰Hospital Regional Universitario de Málaga, Malaga, Spain, ¹¹Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹³Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹⁴Division of Nephrology, Hospital da Costa Burela, Lugo, Spain, ¹⁵Division of Nephrology, Hospital Universitario Lucus Augusti, Lugo, Spain, ¹⁶Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁷Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ¹⁸Basurto University Hospital, Bilbao, Spain, ¹⁹Hospital Universitario de la Princesa, Madrid, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Immunoglobulin-A vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions that share pathophysiological mechanisms1,2. Similar features are also described between IgAV nephritis (IgAVN) and…
Abstract Number: 2409 • ACR Convergence 2023
Concordance of Relapse Symptoms with Initial Baseline Presentation Features Among Patients with Giant Cell Arteritis
Max Guarda¹, Andrew Hanson², Hannah Langenfeld², Cynthia Crowson¹, Jigisha Rakholiya³, Cristian Labarca⁴, Cornelia M. Weyand⁵, Kenneth Warrington¹ and Matthew Koster¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Pueblo, CO, ⁴Clinica Alemana de Santiago, Santiago, Chile, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Relapse is common in giant cell arteritis (GCA) with 40-75% of patients having at least one flare during course of disease. A clinically relevant…
Abstract Number: 2557 • ACR Convergence 2023
Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades
Mahmut Kaymakci¹, Nicholas Boire¹, Melanie Bois¹, Mohanad Elfishawi¹, Hannah Langenfeld², Andrew Hanson², Cynthia Crowson¹, Matthew Koster¹, Cornelia M. Weyand³ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Patients with giant cell arteritis (GCA) are at increased risk of thoracic aortic aneurysm and dissection. This late complication of the disease is presumed…
Abstract Number: 0693 • ACR Convergence 2023
Comparison of the Cardiovascular Risk in Patients with Vasculitis and Diabetes Mellitus
Ana Belen Arevalo¹, Harshvardhan Zala², Andrea Ramirez Gomez¹ and Kichul Ko³, ¹University of Chicago, Chicago, IL, ²Indiana University School of Medicine, Indianapolis, IN, ³The University of Chicago, Chicago, IL
Background/Purpose: Cardiovascular disease (CVD) has been reported as the most common cause of death in ANCA-associated vasculitis (AAV)1,2. Systemic inflammation, in addition to traditional risk…
Abstract Number: 0712 • ACR Convergence 2023
Clinical and Histologic Prognostic Factors of Renal Progression in Adults with IgA Vasculitis
Meenakshi Vanka¹ and Taesoo Kim², ¹Oregon Health & Science University/Emory, Atlanta, GA, ²Oregon Health & Science University, Portland, OR
Background/Purpose: IgA Vasculitis (IgAV) is a systemic small vessel vasculitis that affects the skin, joints, gastrointestinal tract, and kidneys. While most common in children, it…
Abstract Number: 1443 • ACR Convergence 2023
Vasculitis Associations Among Patients with Systemic Lupus Erythematous
Emily Cosentino¹, Mia Blanchard², Diane L. Kamen¹ and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, ²Claremont Graduate University, Claremont, CA
Background/Purpose: Vasculitis is rare manifestation of systemic lupus erythematous (SLE) that often leads to increased morbidity and mortality. Vasculitis prevalence in SLE patients have ranged…
Abstract Number: 1570 • ACR Convergence 2023
Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study
Emma Rinaldi¹, Corrado Campochiaro², Roberto Padoan³, Chengappa Kavadichanda⁴, Augustine Jose⁴, Kritika Singh⁵, Luca Iorio³, Naomi Viapiana⁶, Upendra Rathore⁵, Elena Marina Baldissera⁶, Vikas Agarwal⁵, Lorenzo Dagna⁷, Durga P Misra⁵ and Alessandro Tomelleri⁸, ¹Vita-Salute San Raffaele University, Milan, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³Department of Medicine DIMED, University of Padova, Padova, Italy, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁶IRCCS San Raffaele Hospital, Milan, Italy, ⁷Ospedale San Raffaele, Milano, Italy, ⁸Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy
Background/Purpose: The 2022 ACR/EULAR classification criteria for Takayasu arteritis (TAK) rely on a point-based clinical and imaging scoring system (from 0 to 22). The aim…
Abstract Number: 2373 • ACR Convergence 2023
SIRPα Expression in Systemic Vasculitis
Shubhasree Banerjee¹, Eileen Rose², Sandip Panicker², Nader Khalidi³, Curry Koening⁴, Carol Langford⁵, Paul Monach⁶, Christian Pagnoux⁷, Carol McAlear¹ and Peter Merkel¹, ¹University of Pennsylvania, Philadelphia, PA, ²Electra Therapeutics, Inc., South San Francisco, CA, ³McMaster University, Hamilton, ON, Canada, ⁴University of Texas Dell Medical School, Austin, TX, ⁵Cleveland Clinic, Cleveland, OH, ⁶VA Boston Healthcare System, Boston, MA, ⁷Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Signal regulatory protein alpha (SIRPα) is primarily found on myeloid cells, including macrophages and neutrophils. Upon binding to CD47, SIRPa signaling regulates various cellular…
Abstract Number: 2410 • ACR Convergence 2023
Tocilizumab versus Methotrexate in Giant Cell Arteritis: A Retrospective Study to Compare Efficacy and Rapidity of These Steroid-sparing Agents in GCA Patients
Luca Quartuccio Quartuccio¹, Elena Treppo², Maria De Martino³, Maria Pillon¹, Simone Perniola⁴, Dario Bruno⁴, Miriam Isola³ and Elisa Gremese⁴, ¹Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, ²Physician, Moimacco, Italy, ³Institute of Statistics, Department of Medicine, University of Udine, Udine, Italy, ⁴Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Roma, Italy
Background/Purpose: Glucocorticoids (GCs) are still the mainstay of treatment of Giant Cell Arteritis (GCA). Although GCs are highly effective in GCA, it is well documented…
Abstract Number: 2559 • ACR Convergence 2023
Clinical Manifestations and Immunomodulatory Treatment in Patients with Relapsing Polychondritis
Roger Yang¹, Rennie Rhee², Kaitlin Quinn³, Naomi Amudala², Peter Grayson⁴, Peter Merkel², Marcela Ferrada⁵ and Shubhasree Banerjee², ¹University of Pennsylvania, Montréal, QC, Canada, ²University of Pennsylvania, Philadelphia, PA, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁵NIH, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disease without standard treatment guidelines. This study aims to investigate the clinical characteristics, current treatment approaches,…
Abstract Number: 0028 • ACR Convergence 2023
Adenosine Deaminase 2 Is Expressed as a Short Isoform Lacking Deaminase Activity in the Endothelium: Implications for DADA2 Vasculitis
Andrew Porter¹, Robert Maughan¹, Charis Pericleous¹, Lida Kabir¹, Richard Stratton², Dorian Haskard¹, Pui Lee³, Taryn Youngstein¹ and Justin Mason¹, ¹National Heart & Lung Institute, Imperial College London, London, United Kingdom, ²University College London, London, United Kingdom, ³Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive condition caused by biallelic variants in the Adenosine deaminase 2 (ADA2) gene. Clinical manifestations…
Abstract Number: 0695 • ACR Convergence 2023
Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study
Sabahat Usmani¹, Yanint Raksadawan¹, Amro Taha¹, Harigopal Sandhyavenu¹, Jalpan Patel¹, Thatiana Schulze Goni¹, Hafiz Muhammad Waqar Younas¹ and Irisha Badu², ¹Weiss Memorial Hospital, Chicago, IL, ²Onslow Memorial Hospital, Jacksonville, FL
Background/Purpose: Atrial fibrillation is the most commonly treated cardiac arrhythmia, associated with significant morbidity and mortality. Recent research is suggestive that autoimmunity and inflammation might…
Abstract Number: 0718 • ACR Convergence 2023
Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting
Jeffrey Curtis¹, Lita Araujo², Stefano Fiore², Sebastian Sattui³, John Stone⁴, Kerri Ford² and Fenglong Xie⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Cambridge, MA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁵Illumination Health, Hoover, AL
Background/Purpose: The burden of continuing glucocorticoids (GCs) in patients with polymyalgia rheumatica (PMR) who have an inadequate response (IR)to GCs has not been evaluated.Methods: An…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].